Contextual Genomics Names Sue Paish as Chair of the Board of Directors

VANCOUVER, British Columbia–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/cancergenomics?src=hash" target="_blank"gt;#cancergenomicslt;/agt;–Contextual
Genomics announced today that Sue Paish will become the new Chair of
the Company’s Board of Directors effective May 1, 2019. Ms. Paish joined
the Company’s Board of Directors in 2018 and is the former President and
CEO of LifeLabs Medical Laboratory Services. Mr. Chris Wagner will be
stepping down from his role as Chair, however he will remain as a
Director.

Ms. Paish brings over two decades of growth-focused executive experience
across multiple industries to this role. During her tenure at LifeLabs,
the company grew to become Canada’s largest community laboratory and
leading diagnostic testing provider. She is currently the CEO of the
Digital Technology Supercluster, Chair of the Board of Directors of the
Business Council of British Columbia and a director of CORIX Group.
Prior to her role as CEO of LifeLabs, Ms. Paish was CEO of Pharmasave
and Managing Partner of Fasken, a leading Canadian law firm.

“Sue’s proven experience in strategic growth within the healthcare
industry will aid Contextual Genomics as we continue to advance our
portfolio of end-to-end assays and informatics solutions for cancer
testing designed for rapid deployment into labs” said Michael Ball,
Contextual Genomics’ Chief Executive Officer. “Sue’s business acumen and
knowledge of the diagnostics market will benefit Contextual Genomics’
efforts to enable our partner laboratories to provide access to high
quality and affordable genomic testing worldwide.”`

“As a member of the Contextual Genomics’ Board for the past year, it’s
been a pleasure working with the Company to expand its strategic
laboratory partnerships globally” says Ms. Paish. “The momentum we are
seeing around early access to FOLLOW IT, our ctDNA cancer test, will
continue to expand our commercial adoption and ultimately move us
towards our mission to positively impact cancer treatment.”

About Contextual Genomics (www.contextualgenomics.com):

Contextual Genomics develops cost-effective and clinically actionable
molecular tests that guide cancer treatment decisions. These customized
tests are offered by our partner laboratories around the world with
Contextual Genomics conducting cloud-based bioinformatics services via a
SaaS model. The collection of data via this robust network of partners
and the use of machine-learning tools will allow Contextual Genomics to
improve patient care through improved clinical trial enrolment and new
treatment algorithms. Contextual Genomics is founded and managed by
global leaders in cancer medicine and bioinformatics, who have
unparalleled expertise in cancer genomics and the clonal evolution of
cancer.

About Contextual Genomics’ Products:

The FIND IT^TM and FOLLOW IT^TM cancer panels are
multiplex, next- generation sequencing genomic assays designed for rapid
deployment into labs around the world. Both FIND IT^TM and
FOLLOW IT^TM evaluate the mutation status of tumour DNA (FIND
IT^TM for solid tumours; FOLLOW IT^TM for cell-free
circulating tumour DNA in plasma) at 146 well-characterized positions,
identifying the somatic mutations that have the greatest potential to
impact treatment decisions. QUALITY NEXUS^TM is a quality
control system embedded into all FIND IT^TM and FOLLOW IT^TM
assays and into Contextual Genomics’ cloud-based analysis engine. FIND IT^TM
and FOLLOW IT^TM physician reports provide clear information
on test interpretation and linkages to current therapeutic options.

This release contains forward-looking statements that are not based
on historical fact. These forward-looking statements involve risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from those expressed
or implied by such forward-looking statements. Readers are cautioned not
to place undue reliance on such forward-looking statements.

Contacts

Contextual Genomics
Aubree Hoover
Email: [email protected]